blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2805939

EP2805939 - Heterocyclic compounds as factor IXA inhibitors. [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  03.05.2019
Database last updated on 19.10.2024
FormerThe patent has been granted
Status updated on  25.05.2018
FormerGrant of patent is intended
Status updated on  10.01.2018
FormerExamination is in progress
Status updated on  07.02.2017
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065-0907 / US
[2014/48]
Inventor(s)01 / Clasby, Martin, C.
79 Elsie Drive
Plainsboro, NJ New Jersey 08536 / US
02 / Greenlee, William J.
115 Herrick Avenue
Teaneck, NJ New Jersey 07666 / US
03 / Chackalamannil, Samuel
17 Windy Heights Road
Califon, NJ New Jersey 07830 / US
04 / Xia, Yan
66 Tower Road
Edison, NJ New Jersey 08820 / US
05 / Gao, Xiaobang
1700 Butler Pike, Apt. 6e.
Conshohocken, PA Pennsylvania 19428 / US
06 / Chelliah, Mariappan, V.
56 Portland Street
Edison, NJ New Jersey 08820 / US
07 / Eagen, Keith A.
2 Cindy Lane
Long Valley, NJ New Jersey 07853 / US
08 / Vaccaro, Henry
123 Somerset Avenue
South plainfield, NJ New Jersey 07080 / US
09 / Chan, Tin-yau
26 Barlow Road
Edison, NJ New Jersey 08817 / US
10 / Mckittrick, Brian
14 Millbrook Road
New Vernon, NJ New Jersey 07976 / US
11 / Wang, Li Yuan
39 Scheurman Terrace
Warren, NJ New Jersey 07059 / US
12 / Pu, Haiyan
115 Fellswood Drive
Livingston, NJ New Jersey 07039 / US
 [2014/48]
Representative(s)Hussain, Deeba
Merck Sharp & Dohme Corp.
120 Moorgate
London, EC2M 6UR / GB
[N/P]
Former [2014/48]Hussain, Deeba
Merck & Co., Inc.
Patent Department
Hertford Road
Hoddesdon
Hertfordshire EN11 9BU / GB
Application number, filing date14173412.918.05.2009
[2014/48]
Priority number, dateUS20080054310P19.05.2008         Original published format: US 54310 P
[2014/48]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2805939
Date:26.11.2014
Language:EN
[2014/48]
Type: B1 Patent specification 
No.:EP2805939
Date:27.06.2018
Language:EN
[2018/26]
Search report(s)(Supplementary) European search report - dispatched on:EP29.10.2014
ClassificationIPC:C07D231/18, C07D487/04, C07D401/04, C07D403/04, C07D413/04, C07D413/14, C07D403/14, C07D401/14, A61P7/02, A61K31/416, A61K31/415, A61K31/4155, A61K31/4152
[2014/48]
CPC:
C07D487/04 (EP,US); A61P7/02 (EP); A61P9/06 (EP);
A61P9/10 (EP); C07D231/18 (EP,US); C07D401/04 (EP,US);
C07D401/14 (EP,US); C07D403/04 (EP,US); C07D403/14 (EP,US);
C07D413/04 (EP,US); C07D413/14 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2015/27]
Former [2014/48]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:Heterocyclische Verbindungen als Faktor-IXA-Inhibitoren[2014/48]
English:Heterocyclic compounds as factor IXA inhibitors.[2014/48]
French:Composés hétérocycliques en tant qu'inhibiteurs de facteur IXA[2014/48]
Examination procedure26.05.2015Examination requested  [2015/27]
03.07.2015Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
09.09.2015Amendment by applicant (claims and/or description)
10.03.2016Despatch of a communication from the examining division (Time limit: M06)
16.09.2016Reply to a communication from the examining division
27.01.2017Despatch of a communication from the examining division (Time limit: M06)
07.08.2017Reply to a communication from the examining division
11.01.2018Communication of intention to grant the patent
10.05.2018Receipt of the translation of the claim(s)
11.05.2018Fee for grant paid
11.05.2018Fee for publishing/printing paid
Parent application(s)   TooltipEP09751268.5  / EP2300435
Opposition(s)28.03.2019No opposition filed within time limit [2019/23]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
09.09.2015Request for further processing filed
09.09.2015Full payment received (date of receipt of payment)
Request granted
21.09.2015Decision despatched
Fees paidRenewal fee
23.10.2014Renewal fee patent year 03
23.10.2014Renewal fee patent year 04
23.10.2014Renewal fee patent year 05
29.09.2014Renewal fee patent year 06
07.05.2015Renewal fee patent year 07
30.03.2016Renewal fee patent year 08
08.05.2017Renewal fee patent year 09
07.05.2018Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU18.05.2009
AT27.06.2018
CY27.06.2018
CZ27.06.2018
DK27.06.2018
EE27.06.2018
ES27.06.2018
FI27.06.2018
HR27.06.2018
IT27.06.2018
LT27.06.2018
LV27.06.2018
MC27.06.2018
MK27.06.2018
MT27.06.2018
NL27.06.2018
PL27.06.2018
RO27.06.2018
SE27.06.2018
SI27.06.2018
SK27.06.2018
TR27.06.2018
BG27.09.2018
NO27.09.2018
GR28.09.2018
IS27.10.2018
PT29.10.2018
[2022/31]
Former [2021/34]HU18.05.2009
AT27.06.2018
CY27.06.2018
CZ27.06.2018
DK27.06.2018
EE27.06.2018
ES27.06.2018
FI27.06.2018
HR27.06.2018
IT27.06.2018
LT27.06.2018
LV27.06.2018
MC27.06.2018
MT27.06.2018
NL27.06.2018
PL27.06.2018
RO27.06.2018
SE27.06.2018
SI27.06.2018
SK27.06.2018
TR27.06.2018
BG27.09.2018
NO27.09.2018
GR28.09.2018
IS27.10.2018
PT29.10.2018
Former [2021/32]HU18.05.2009
AT27.06.2018
CY27.06.2018
CZ27.06.2018
DK27.06.2018
EE27.06.2018
ES27.06.2018
FI27.06.2018
HR27.06.2018
IT27.06.2018
LT27.06.2018
LV27.06.2018
MC27.06.2018
NL27.06.2018
PL27.06.2018
RO27.06.2018
SE27.06.2018
SI27.06.2018
SK27.06.2018
TR27.06.2018
BG27.09.2018
NO27.09.2018
GR28.09.2018
IS27.10.2018
PT29.10.2018
Former [2021/26]AT27.06.2018
CY27.06.2018
CZ27.06.2018
DK27.06.2018
EE27.06.2018
ES27.06.2018
FI27.06.2018
HR27.06.2018
IT27.06.2018
LT27.06.2018
LV27.06.2018
MC27.06.2018
NL27.06.2018
PL27.06.2018
RO27.06.2018
SE27.06.2018
SI27.06.2018
SK27.06.2018
TR27.06.2018
BG27.09.2018
NO27.09.2018
GR28.09.2018
IS27.10.2018
PT29.10.2018
Former [2020/29]AT27.06.2018
CZ27.06.2018
DK27.06.2018
EE27.06.2018
ES27.06.2018
FI27.06.2018
HR27.06.2018
IT27.06.2018
LT27.06.2018
LV27.06.2018
MC27.06.2018
NL27.06.2018
PL27.06.2018
RO27.06.2018
SE27.06.2018
SI27.06.2018
SK27.06.2018
TR27.06.2018
BG27.09.2018
NO27.09.2018
GR28.09.2018
IS27.10.2018
PT29.10.2018
Former [2020/16]AT27.06.2018
CZ27.06.2018
DK27.06.2018
EE27.06.2018
ES27.06.2018
FI27.06.2018
HR27.06.2018
IT27.06.2018
LT27.06.2018
LV27.06.2018
MC27.06.2018
NL27.06.2018
PL27.06.2018
RO27.06.2018
SE27.06.2018
SI27.06.2018
SK27.06.2018
TR27.06.2018
BG27.09.2018
NO27.09.2018
GR28.09.2018
IS27.10.2018
Former [2020/07]AT27.06.2018
CZ27.06.2018
DK27.06.2018
EE27.06.2018
ES27.06.2018
FI27.06.2018
HR27.06.2018
IT27.06.2018
LT27.06.2018
LV27.06.2018
MC27.06.2018
NL27.06.2018
PL27.06.2018
RO27.06.2018
SE27.06.2018
SI27.06.2018
SK27.06.2018
BG27.09.2018
NO27.09.2018
GR28.09.2018
IS27.10.2018
Former [2019/37]AT27.06.2018
CZ27.06.2018
DK27.06.2018
EE27.06.2018
ES27.06.2018
FI27.06.2018
HR27.06.2018
IT27.06.2018
LT27.06.2018
LV27.06.2018
NL27.06.2018
PL27.06.2018
RO27.06.2018
SE27.06.2018
SI27.06.2018
SK27.06.2018
BG27.09.2018
NO27.09.2018
GR28.09.2018
IS27.10.2018
Former [2019/26]AT27.06.2018
CZ27.06.2018
DK27.06.2018
EE27.06.2018
ES27.06.2018
FI27.06.2018
HR27.06.2018
IT27.06.2018
LT27.06.2018
LV27.06.2018
NL27.06.2018
PL27.06.2018
RO27.06.2018
SE27.06.2018
SK27.06.2018
BG27.09.2018
NO27.09.2018
GR28.09.2018
IS27.10.2018
Former [2019/12]AT27.06.2018
CZ27.06.2018
EE27.06.2018
ES27.06.2018
FI27.06.2018
HR27.06.2018
IT27.06.2018
LT27.06.2018
LV27.06.2018
NL27.06.2018
PL27.06.2018
RO27.06.2018
SE27.06.2018
SK27.06.2018
BG27.09.2018
NO27.09.2018
GR28.09.2018
IS27.10.2018
Former [2019/11]AT27.06.2018
CZ27.06.2018
EE27.06.2018
FI27.06.2018
HR27.06.2018
IT27.06.2018
LT27.06.2018
LV27.06.2018
NL27.06.2018
PL27.06.2018
RO27.06.2018
SE27.06.2018
SK27.06.2018
BG27.09.2018
NO27.09.2018
GR28.09.2018
IS27.10.2018
Former [2019/10]AT27.06.2018
CZ27.06.2018
EE27.06.2018
FI27.06.2018
HR27.06.2018
LT27.06.2018
LV27.06.2018
NL27.06.2018
PL27.06.2018
RO27.06.2018
SE27.06.2018
SK27.06.2018
BG27.09.2018
NO27.09.2018
GR28.09.2018
IS27.10.2018
Former [2019/09]EE27.06.2018
FI27.06.2018
HR27.06.2018
LT27.06.2018
LV27.06.2018
NL27.06.2018
SE27.06.2018
BG27.09.2018
NO27.09.2018
GR28.09.2018
IS27.10.2018
Former [2019/08]FI27.06.2018
HR27.06.2018
LT27.06.2018
LV27.06.2018
NL27.06.2018
SE27.06.2018
BG27.09.2018
NO27.09.2018
GR28.09.2018
IS27.10.2018
Former [2019/03]FI27.06.2018
HR27.06.2018
LT27.06.2018
LV27.06.2018
NL27.06.2018
SE27.06.2018
BG27.09.2018
NO27.09.2018
GR28.09.2018
Former [2018/52]FI27.06.2018
HR27.06.2018
LT27.06.2018
LV27.06.2018
SE27.06.2018
BG27.09.2018
NO27.09.2018
GR28.09.2018
Former [2018/51]FI27.06.2018
HR27.06.2018
LT27.06.2018
LV27.06.2018
SE27.06.2018
BG27.09.2018
NO27.09.2018
Former [2018/50]FI27.06.2018
HR27.06.2018
LT27.06.2018
SE27.06.2018
BG27.09.2018
NO27.09.2018
Former [2018/49]FI27.06.2018
LT27.06.2018
SE27.06.2018
BG27.09.2018
NO27.09.2018
Former [2018/47]FI27.06.2018
LT27.06.2018
NO27.09.2018
Documents cited:Search[X]WO2005030128  (MERCK & CO INC [US], et al) [X] 1 * last compound on page 34;; claim 1 *;
 [X]WO2006014618  (MERCK & CO INC [US], et al) [X] 1 * example 42; claim 1 *;
 [X]WO2006017055  (MERCK & CO INC [US], et al) [X] 1 * examples 51-53; claim 1 *;
 [X]WO2006033943  (EXELIXIS INC [US], et al) [X] 1 * example 9; claim 1 *;
 [X]WO2007061923  (TAKEDA SAN DIEGO INC [US], et al) [X] 1 * the 6th compound of page 180;; claim 1 *;
 [XD]  - VIJAYKUMAR D ET AL, "Discovery of novel hydroxy pyrazole based factor IXa inhibitor", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 16, no. 10, ISSN 0960-894X, (20060515), pages 2796 - 2799, (20060515), XP025106845 [XD] 1-27 * table 1; compounds 2-4 *

DOI:   http://dx.doi.org/10.1016/j.bmcl.2006.01.123
 [X]  - ANDREICHIKOV, YU. S. ET AL, "Dihydro-1,2-diazaphenazines", CA, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, Database accession no. 1975:97992, URL: STN, XP002730736 [X] 1 * abstract *

DOI:   http://dx.doi.org/10.1007/BF00474336
by applicantEP0028489
 WO9403479
 US5612359
 WO0001389
 US6043265
 US6063847
 WO0140231
 US6326380
 WO0196330
 EP1294714
 US6645987
 EP1495018
 US7037920
 US7235567
 US7304078
    - VIJAYKUMAR ET AL., BIORGANIC & MEDICINAL CHEMISTRY LETTERS, (2006), vol. 16, no. 10, pages 2796 - 2799
    - HOWARD, EL; BECKER KC; RUSCONI, CP; BECKER RC, "Factor IXa Inhibitors as Novel Anticoagulents", ARTERIOSCLER THROMB VASC BIOL., (2007), vol. 27, pages 722 - 727
    - MONROE DM; HOFFMAN M; ROBERTS HR, "Platelets and thrombin generation", ARTERIOSCLER THROMB VASC BIOL., (2002), vol. 22, pages 1381 - 1389
    - AHMAD SS; LONDON FS; WALSH PN, "The assembly of the factor X-activating complex on activated human platelets", J THROMB HAEMOST., (2003), vol. 1, pages 48 - 59
    - KOMIYAMA Y; PEDERSEN AH; KISIEL W., "Proteolytic activation of human factors IX and X by recombinant human factor Vila: effects of calcium, phospholipids, and tissue factor", BIOCHEMISTRY, (1990), vol. 29, pages 9418 - 9425
    - BROZE GJ; WARREN LA; NOVOTNY WF; HIGUCHI DA; GIRARD JJ; MILETICH PJ, "The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action", BLOOD, (1988), vol. 71, pages 335 - 343
    - RAPAPORT SI, "The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation", THROMB HAEMOST, (1991), vol. 66, pages 6 - 15
    - MONKOVIC DD; TRACY PB, "Activation of human factor V by factor Xa and thrombin", BIOCHEMISTRY, (1990), vol. 29, pages 1118 - 1128
    - HOFFMAN M; MONROE DM; OLIVER JA; ROBERTS HR, "Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation", BLOOD, (1995), vol. 86, pages 1794 - 1801
    - MONROE DM; HOFFMAN M; ROBERTS HR, "Transmission of a procoagulant signal from tissue factor-bearing cells to platelets", BLOOD COAGUL FIBRINOLYSIS., (1996), vol. 7, pages 459 - 464
    - WALSH PN; SINHA D; KOSHY A; SEAMAN FS; BRADFORD H, "Functional characterization of platelet-bound factor Xla: retention of factor Xla activity on the platelet surface", BLOOD, (1986), vol. 68, pages 225 - 230
    - FRANSSEN J; SALEMINK; WILLEMS GM; WUN TC; HEMKER HC; LINDHOUT T, "Prothrombinase is protected from inactivation by tissue factor pathway inhibitor: competition between prothrombin and inhibitor", BIOCHEM J., (1997), vol. 323, pages 33 - 37
    - REZAIE AR, "Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex", BLOOD, (2001), vol. 97, pages 2308 - 2313
    - LAWSON JH; MANN KG, "Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation", J BIOL CHEM., (1991), vol. 266, pages 11317 - 11327
    - "Pro-drugs as Novel Delivery Systems", T. HIGUCHI; V. STELLA, A.C.S. Symposium Series, (1987), vol. 14
    - "Pro-drugs as Novel Delivery Systems", T. HIGUCHI; W. STELLA, A.C.S. Symposium Series, vol. 14
    - M. CAIRA ET AL., J. PHARMACEUTICAL SCI., (2004), vol. 93, no. 3, pages 601 - 611
    - A. L. BINGHAM ET AL., CHEM. COMMUN., (2001), pages 603 - 604
    - S. BERGE ET AL., JOURNAL OF PHARMACEUTICAL SCIENCES, (1977), vol. 66, no. 1, pages 1 - 19
    - P. GOULD, INTERNATIONAL J. OF PHARMACEUTICS, (1986), vol. 33, pages 201 - 217
    - The Orange Book, FOOD & DRUG ADMINISTRATION
    - BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, (2002), vol. 12, pages 2019 - 2022
    - J. MED. CHEM., (2005), pages 1873 - 1885
    - BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, (2006), vol. 16, pages 1486 - 1490
    - CHOU; TALALAY, ADV. ENZYME REGUL., (1984), vol. 22, pages 27 - 55
    - BERNATOWICZ ET AL., J. MED. CHEM., (1996), vol. 39, pages 4879 - 4887
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.